270 related articles for article (PubMed ID: 14568829)
21. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
23. Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy.
Rullan P; Murase J
J Drugs Dermatol; 2009 Sep; 8(9):873-6. PubMed ID: 19746681
[TBL] [Abstract][Full Text] [Related]
24. Etanercept in the treatment of palmoplantar pustulosis.
Bissonnette R; Poulin Y; Bolduc C; Maari C; Provost N; Syrotuik J; Poulin-Costello CM; Nigen S
J Drugs Dermatol; 2008 Oct; 7(10):940-6. PubMed ID: 19112757
[TBL] [Abstract][Full Text] [Related]
25. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
Cassano N; Loconsole F; Galluccio A; Miracapillo A; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2006; 19(1):225-9. PubMed ID: 16569361
[TBL] [Abstract][Full Text] [Related]
26. The effect of etanercept on Graves' ophthalmopathy: a pilot study.
Paridaens D; van den Bosch WA; van der Loos TL; Krenning EP; van Hagen PM
Eye (Lond); 2005 Dec; 19(12):1286-9. PubMed ID: 15550932
[TBL] [Abstract][Full Text] [Related]
27. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
28. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
29. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept.
Yamauchi PS; Turner L; Lowe NJ; Gindi V; Jackson JM
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S122-6. PubMed ID: 16488324
[No Abstract] [Full Text] [Related]
30. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
31. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
Luger TA; Barker J; Lambert J; Yang S; Robertson D; Foehl J; Molta CT; Boggs R
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
[TBL] [Abstract][Full Text] [Related]
32. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis.
Safa G; Loppin M; Bousser AM; Barbarot S
J Am Acad Dermatol; 2007 Feb; 56(2 Suppl):S19-20. PubMed ID: 17097376
[No Abstract] [Full Text] [Related]
33. [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept].
Mrowietz U; Barth J; Boehncke WH; Rosenbach T; Wozel G
J Dtsch Dermatol Ges; 2005 Jun; 3(6):470-2. PubMed ID: 15892851
[No Abstract] [Full Text] [Related]
34. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome.
Quillinan N; Mannion G; Mohammad A; Coughlan R; Dickie LJ; McDermott MF; McGonagle D
Ann Rheum Dis; 2011 Sep; 70(9):1692-3. PubMed ID: 21378401
[No Abstract] [Full Text] [Related]
35. Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option.
Tausche AK; Richter K; Grässler A; Hänsel S; Roch B; Schröder HE
Ann Rheum Dis; 2004 Oct; 63(10):1351-2. PubMed ID: 15361402
[No Abstract] [Full Text] [Related]
36. The use of etanercept in the treatment of peristomal pyoderma gangrenosum.
Kim FS; Pandya AG
Clin Exp Dermatol; 2012 Jun; 37(4):442-3. PubMed ID: 22582915
[No Abstract] [Full Text] [Related]
37. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept.
Field S; Regan AO; Sheahan K; Collins P
Clin Exp Dermatol; 2010 Oct; 35(7):795-6. PubMed ID: 20831604
[No Abstract] [Full Text] [Related]
38. Wider use for Enbrel.
FDA Consum; 2003; 37(6):7. PubMed ID: 14983814
[No Abstract] [Full Text] [Related]
39. Survival rate of etanercept for psoriasis in real life: a multicentre observational study.
Herrera-Acosta E; Suárez-Pérez JA; Aguilera J; Gómez-García F; Jiménez-Puya R; Guimerá F; Mendiola MV; Herrera-Ceballos E
Eur J Dermatol; 2014; 24(5):619-20. PubMed ID: 25115194
[No Abstract] [Full Text] [Related]
40. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
Martínez-Abundis E; Reynoso-von Drateln C; Hernández-Salazar E; González-Ortiz M
Arch Dermatol Res; 2007 Nov; 299(9):461-5. PubMed ID: 17726611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
